Opendata, web and dolomites

RheoCare SIGNED

Rheological Monitoring of Chronic Respiratory Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RheoCare project word cloud

Explore the words cloud of the RheoCare project. It provides you a very rough idea of what is the project "RheoCare" about.

crises    point    regarding    pulmonary    periodic    attractively    2020    forecast    trials    healthcare    g8    attractive    first    treatments    market    group    infections    commercialised    cf    assessing    diseases    irreversible    supporting       assesses    quantitatively    exacerbation    5b    rheocare    efficiency    building    structures    plug    secretions    patients    protected    priced    ip    fibrosis    segment    lower    accompanied    treatment    rheonova    personalised    biomarker    ambition    demonstrated    software    minutes    commercialisation    machine    reproducibility    lung    24k    benefit    patent    worldwide    mucus    causing    clinical    automated    samples    patient    techniques    crisis    performance    plan    rheometer    choose    china    manipulation    emergency    protocols    specificity    chronic    capacity    exist    care    biomarkers    predicting    feasibility    acute    device    technique    eight    remoulding    medical    robustness    antibioresistances    develops    complete    phases    hospitalisations    mortality    rheology    cystic    80    airways    play    strategy    favouring    respiratory    consumables    monitoring    block    spectrum    quantitative   

Project "RheoCare" data sheet

The following table provides information about the project.

Coordinator
RHEONOVA SAS 

Organization address
address: 31 BOULEVARD AGUTTE SEMBAT
city: GRENOBLE
postcode: 38000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RHEONOVA SAS FR (GRENOBLE) coordinator 50˙000.00

Map

 Project objective

Chronic respiratory diseases are expected to become the third cause of mortality worldwide by 2020. Patients experience periodic acute exacerbation phases favouring infections of the lower airways and causing irreversible loss of pulmonary capacity. These crises cannot be forecast with current techniques and require emergency hospitalisations, leading to healthcare costs (€24k per crisis) and antibioresistances due to wide-spectrum treatments. Among respiratory diseases, we choose to target cystic fibrosis (CF) in Europe as organised care structures pre-exist. CF also represents a very attractive market segment of $4.5B across the Group of Eight (G8). Rheonova develops a unique monitoring test based on the rheology of lung secretions (mucus). The RheoCare project will provide a dedicated plug-and-play rheometer, with a quantitative biomarker and a specificity above 80%, allowing a point-of-care CF monitoring test within 10 minutes as a first step towards personalised healthcare. Our four-patent-protected technique already assesses treatments efficiency and is commercialised to researchers. Phase 1 clinical trials have demonstrated the reproducibility and the robustness of our biomarkers. Two new clinical protocols (Phase 2) proceed in order to demonstrate the medical benefit for the patient, i.e. the reduction of hospitalisations by predicting the exacerbation phases and assessing treatment performance quantitatively. Within three years, Phase 3 clinical trials will support the commercialisation of the device in EU and China. We will address the medical market with an attractively-priced machine accompanied with specific consumables needed to test mucus samples. To support our ambition, we need to implement an automated sample manipulation device. Three priority tasks remain to complete the feasibility study: (i) remoulding the software, (ii) supporting our commercialisation plan, and (iii) defining the IP strategy regarding this new building block.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEOCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHEOCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

STURSKIN (2018)

Innovative products by using tanned sturgeon skin

Read More